SUMMIT DETAILS
Since the inaugural meeting held at the Royal Society in London 2013, The E-Cigarette Summit has been at the forefront of expanding and forwarding the scientific and public health discussions around e-cigarettes and broader harm reduction debates. Now, eight years on the Summit welcomes scientists, regulators, public health professionals and policy makers from around the world who are looking to establish their own regulatory framework in the face of new nicotine products.
There’s no doubt that the global dialogue surrounding Tobacco Harm Reduction (THR) and specifically e-cigarettes has become increasingly fraught. The EVALI crisis and rising youth use reported during 2019, intensified what was already an emotional and divisive debate and the impact on global Governmental actions and public confidence in vaping has been significant. During this time of global uncertainty around the benefits and risks of e-cigarettes a sober analysis of THR in all of its ramifications has perhaps never been more necessary. 2021 will be another Watershed year for electronic cigarettes, the UK’s departure from the European Union, the upcoming European Tobacco Product Directive’s review and the imminent announcements and implementation of the PMTA will all have material impacts on the regulatory and policy environment for e-cigarettes and reduced risk products.
2021 TOPICS
Smoking is the biggest single cause of preventable death in the developed world with almost 1 billion users worldwide. Despite decades of tobacco control efforts and public health education on the harms of smoking, the decline in smoking rates has been frustratingly slow. The E-Cigarette Summit provides a much-needed neutral platform to explore the available peer reviewed evidence and debate the issues that are dividing scientists, health professionals and policy makers alike. The E-Cigarette Summit has a single aim of facilitating respectful dialogue and thoughtful analysis of the latest research and to discuss how the evidence should be interpreted and communicated to deliver the most effective health strategies to reduce smoking related death and disease.
DAY ONE: 7 DECEMBER 2021
DAY TWO: 8 DECEMBER 2021
Session 1: Science & Evidence
- OPENING KEYNOTE What will success look like?
- Depolarizing E-Cigarette Research: The need for epistemic humility
- Do e-cigarettes help people quit smoking? A plea to focus on the evidence
- The need to unbias the application of competing interest principles in e-cigarette research
- Could e-cigarettes contribute to harm reduction for children as well as adults?
Session 2: Tobacco Harm Reduction & Tobacco Control
- Is there a place for low-risk nicotine ‘alternatives’ on the market when smoking is about to disappear?
- The tobacco control climate in Germany
- Reconsidering the meaning of tobacco harm reduction
- Australia doubles down on its e-cigarette sales ban
- The new tobacco wars
Session 3: Tobacco control, Regulation & Enforcement
- The MHRA Regulatory Update
- Trading standards and enforcement in the UK
- Balancing regulation to achieve intended consequences
- UK Policy and regulation
Session 4: Tobacco Harm Reduction & Public Health Policy
- Vaping in the UK – Steady as she goes
- Title TBC
- The 2021 review of NICE’s tobacco guidelines
- Combustible Tobacco Age-of-Sale Laws: An Opportunity?
- The potential role of the cigarette industry in the future of the e-cigarette market
Session 5: Tobacco Harm Reduction, Research & Policy
- E-cigarette research: Misinterpretation and selective use of evidence guiding regulatory decisions
- Absolute and relative risks of electronic cigarettes
- Nicotine and pregnant smokers
- The impact of the COVID-19 pandemic on e-cigarette and tobacco use in the UK
- Depression causes vaping!
Session 6: Nicotine & Public Health
- Shifting the Paradigm: Tobacco Control and Tobacco Harm Reduction are Scientifically Complementary Approaches
- Parents: The Untapped Resource for Balancing Cessation and Prevention Needs
- Meeting people where they are and not where we think they should be
- How tobacco harm reduction pragmatism has opened up opportunities for smokers facing severe disadvantage
- CLOSING KEYNOTE: Covid-19 and tobacco harm reduction: are there lessons from the pandemic for the way ahead?
Paul Lincoln OBE
Chair - Tobacco: preventing uptake, promoting quitting and treating tobacco dependence
(NICE) National Institute of Clinical and Health Excellence -
Dr Colin Mendelsohn MB BS (Hons)
General practitioner, Founding Chairman
Australian Tobacco Harm Reduction Association
Louise Ross
Interim Chair and Mental Health Lead for the New Nicotine Alliance
Business Development Manager - Smoke Free - Quit Smoking Now
Prof Daniel Kotz
Professor in addiction research and clinical epidemiology, Institute of General Practice
Centre for Health and Society, Medical Faculty of the Heinrich-Heine-University Düsseldorf, Germany
Prof Linda Bauld, OBE
Bruce and John Usher Chair in Public Health in the Usher Institute
College of Medicine, University of Edinburgh
Prof Lion Shahab
Professor of Health Psychology
Department of Behavioural Science and Health, University College London
Dr Michael Pesko
Health Economist & Associate Professor
Department of Economics, Andrew Young School of Policy Studies, Georgia State University
Andrea Crossfield MBE
Independent Public Health Consultant and Population Health Policy Specialist
Greater Manchester Health and Social Care Partnership
Prof Alan Boobis, OBE
Emeritus Professor of Toxicology & Chair - UK Committee on Toxicity
Imperial College London
Prof Ann McNeill
Professor of Tobacco Addiction
Institute of Psychiatry, Psychology & Neuroscience,, Kings College London
Kate Pike
Co-ordinator - Trading Standards North West
Member of the Department of Health and Social Care National Tobacco Focus Group
Craig Copland
E-Cigarette Unit Manager - Vigilance and Risk Management of Medicines
MHRA - The Medicines and Healthcare products Regulatory Agency
Dr Debbie Robson RMN, PhD
Senior Lecturer in Tobacco Harm Reduction
National Addiction Centre, Institute of Psychiatry, Psychology & Neuroscience, King’s College London
Rosanna O’Connor
Director, Addictions & Inclusion
Office for Health Improvement & Disparities, Department of Health and Social Care
Professor Marcus Munafò
Professor of Biological Psychology and MRC Investigator
School of Psychological Science, University of Bristol
Prof Thomas J. Glynn, PhD
Adjunct Lecturer
Stanford Prevention Research Center, Stanford University School of Medicine
Prof Wayne Hall
Professor Emeritus, National Centre for Youth Substance Use Research
The University of Queensland
Prof Martin Jarvis
Emeritus Professor of Health Psychology, Department of Behavioural Science & Health
University College London
Prof Robert Beaglehole
Emeritus Professor
University of Auckland, New Zealand & Chair ASH - Action for Smokefree 2025, NZ
Prof Robin Mermelstein
Distinguished Professor of Psychology & Director, Institute for Health Research and Policy
University of Illinois, Chicago
Cliff Douglas JD
Director, Tobacco Research Network, Adjunct Professor, Dep't of Health Management and Policy
University of Michigan School of Public Health
Dr Jamie Hartmann-Boyce
Managing Editor, Cochrane Tobacco Addiction Group & Senior Research Fellow
University of Oxford
Dr Konstantinos Farsalinos M.D
External Research Associate
University of Patras, Department of Public and Community Health, University of West Attica, Greece
Prof Peter Hajek
Professor of Clinical Psychology
Wolfson Institute of Public Health, Queen Mary University of London
